(Reuters) – Britain’s drug regulator is set to make 25% of its staff redundant amid financial pressures, with up to 300 staff members being at risk of losing their jobs, the Financial Times reported on Friday.
Senior personnel at the Medicines and Healthcare products Regulatory Agency (MHRA) have expressed “deep concern” over the plans, the report added, citing a letter to the agency’s board by senior staff.
The need for budget cuts at the MHRA is driven in part by Brexit and the loss of millions of pounds of annual income from its role authorising medicines in the European Union. It has also been caused by a squeeze in government funding, the FT said.
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.